CLVS image

Clovis Oncology, Inc (CLVS) stock jumps 8% on positive results in cancer trial

CLVS – Clovis has a successful new ovarian cancer treatment.


Clovis Oncology, Inc (NASDAQ:CLVSis seeing a boost after positive developments 

Progression free survival was shown to be effective with the cancer treatment based on a trial against a placebo. Three sub groups of women were surveyed, including ovarian, fallopian tube, and primary peritoneal cancers, and all showed positive results.

Market Watch provides details on the exciting advancement:

“If approved, Rubraca would have the broadest label of any PARP inhibitor in ovarian cancer… which we think should bode well for the commercial uptake of the drug,” Schmidt said, calling the company a prime takeout candidate.

The trial enrolled 564 women, and FDA approval will be established within four months.

Clovis Oncology, Inc shares rose $0.19 (+0.72%) in after-hours trading Friday. Year-to-date, CLVS has declined -61.24%, versus a 4.87% rise in the benchmark S&P 500 index during the same period.

CLVS currently has a StockNews.com POWR Rating of F (Strong Sell), and is ranked #192 of 312 stocks in the Biotech category.

CLVS at a Glance

CLVS Current POWR Rating™
Overall POWR Rating™
CLVS Current Price $15.08 1.18%
More CLVS Ratings, Data, and News

CLVS Price Reaction

The day of this event (Oct. 19, 2018)
CLVS Closing Price$26.36 12.02%
CLVS Volume6,149,100
400.65% from avg
Leading up to this event
CLVS 1-mo return6.99%
After this event
CLVS 1-day return41.86%
CLVS 3-day return66.40%
CLVS 5-day return66.63%

CLVS Price Chart



More Clovis Oncology, Inc. (CLVS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLVS News
Page generated in 0.8304 seconds.